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As the most important viral cause of severe respiratory disease in
infants and increasing recognition as important in the elderly and
immunocompromised, respiratory syncytial virus (RSV) is
responsible for a massive health burden worldwide. Prophylactic
antibodies were successfully developed against RSV. However, their
use is restricted to a small group of infants considered at high risk of
severe RSV disease. There is still no specific therapeutics or vaccines
to combat RSV. As such, it remains a major unmet medical need for
most individuals. The World Health Organisations International
Clinical Trials Registry Platform (WHO ICTRP) and PubMed were
used to identify and review all RSV vaccine, prophylactic and
therapeutic candidates currently in clinical trials. This review
presents an expert commentary on all RSV-specific prophylactic and
therapeutic candidates that have entered clinical trials since 2008.
Keywords respiratory syncytial virus, respiratory syncytial virus
antivirals, respiratory syncytial virus prophylactic antibodies, respi-
ratory syncytial virus vaccines.
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Introduction
Discovered in 1956, respiratory syncytial virus (RSV) was
quickly identified as the leading cause of lower respiratory
tract infections (LRTI) in infants worldwide.1 Respiratory
syncytial virus is a member of the Paramyxoviridae family,
Pneumovirus genus. With a 152-kB single-stranded negative
sense RNA genome, RSV contains 10 genes encoding 11
proteins, including the fusion (F) and attachment (G) surface
glycoproteins, which constitute the principle target antigens
for RSV vaccines. Two RSV subgroups exist (A and B),
distinguished primarily by genetic and antigenic differences
in the G gene and protein. Respiratory syncytial virus virions
have two reported forms: spherical particles (≤300 nm
diameter) and long filamentous forms (2–10 lm).2,3 Respi-
ratory syncytial virus is responsible for up to 338 million
LRTI cases yearly, approximately 34 million hospitalisations
and up to 199 000 deaths worldwide, predominantly in
developing countries.4,5 For example, Kenya reported RSV-
related LRTI rates of 7100/100 000 in children <5 years6
versus 1042/100 000 in England.7 Furthermore, in many
countries, RSV is comparable to influenza regarding mor-
tality rates and health and economic burdens in children.8
Symptoms such as rhinorrhea, coryza, sore throat and
malaise are features of mild RSV infection.9 Clinical signs of
RSV-LRTI include dyspnoea, cyanosis, subcostal recession,
low-grade fever, wheezing and consolidation.10,11 RSV-LRTI
is responsible for 85% of bronchiolitis and 20% of
pneumonia in infants.12 In the first year of life, 1–3% of
infants are hospitalised with severe RSV-LRTI. Mechanical
ventilation is required in 10% of hospitalised infants, of
which 5–10% succumb to RSV infection.
Risk factors associated with the development of severe
RSV-LRTI include the following: prematurity; bronchopul-
monary dysplasia; congenital lung or heart conditions; male
gender; age ≤6 months; neuromuscular disorders; and
immunodeficiency. Trisomy 21 and cystic fibrosis were also
recently identified as possible risk factors.13
There are no effective vaccines or specific drugs against
RSV. Treatment has remained largely unchanged since the
1960s and is mainly supportive. A number of Cochrane
reviews have noted short-term clinical benefit in the use of
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nebulised adrenaline.14 However, meta-analyses on hyper-
tonic saline, bronchodilator and glucocorticoid use have not
shown clinical benefit,15,16 and currently, only supportive
management is recommended.
Recently, there has been a tremendous increase in interest
and investment within the pharmaceutical sector in vaccine
and drug development against RSV. Several exciting devel-
opments are being pursued and optimism is high that
effective RSV drugs and vaccines are achievable.
Methods
All clinical trials relating to vaccines, prophylactics or
therapeutics against RSV were identified by searching the
World Health Organisation International Clinical Trials
Registry Platform (WHO ICTRP) (www.who.int/trial-
search/) for the terms ‘RSV’ or ‘respiratory syncytial virus’.17
The WHO ICTRP search portal includes all internationally
recognised clinical trial databases. See Appendix 1.
Clinical and preclinical information on each agent was
identified through PubMed by searching for the drug/vaccine
names/clinical trial identifier. MeSH search protocols and
free-text searches were used to ensure no relevant data were
omitted. Where no peer-reviewed published data was found,
additional experimental information was sought directly
either from the manufacturer18 or from patents describing
the specified pharmaceutical.
Pharmaceuticals that underwent clinical trials before 2008
but with no subsequent published information or outcomes
were excluded from this review, as we considered that they
constituted discontinued drug/vaccine developments.
Results of search
In January 2015, the WHO ICTRP search portal identified
160 trials registered relating to RSV. Fifty-four trials pre-2008
with no published outcomes were excluded. Of the remain-
ing 106, a further 61 trials were excluded due to irrelevance
to the topic, duplication, non-drug trials or trials that did not
involve new RSV drugs (Table 1). In total, 45 relevant entries
relating to the prevention or treatment of RSV were
identified. These trials corresponded to 24 different drugs,
including 5 prophylactics, 9 therapeutics and 10 vaccines (see
Table 2 for details). The vaccines, prophylactics and thera-
peutics currently undergoing clinical trials are described
below. This review presents a comprehensive overview of
current strategies undergoing clinical development for the
clinical management of RSV.
Current state of advancement of vaccine,
prophylactic and therapeutic options for RSV in
clinical development
Vaccines
No RSV vaccine has been licensed to date. Enhanced disease
following natural RSV infection in the wake of the infamous
formalin-inactivated alum-adjuvanted RSV vaccine (FI-
RSV)19 effectively led to a moratorium on the study of
inactivated or subunit RSV vaccine candidates in RSV-na€ıve
infants. Since then, further vaccine development has been
impeded by the need to create robust immune responses
without causing vaccine-enhanced illness.20 As peak inci-
dence of severe disease occurs between 6 weeks and
6 months, a RSV vaccine would ideally be administered
within the 1st month of life. However, immune immaturity
and the presence of maternal antibodies that may negatively
impact on vaccine effectiveness are difficult hurdles to
overcome in infant vaccine development. Despite these
considerable barriers and historical setbacks, there is evi-
dence to suggest that a RSV vaccine is feasible. First, while
RSV infection occurs repeatedly throughout life, the fre-
quency of severe disease decreases in second and subsequent
infections.21,22 Furthermore, the monoclonal antibody
(MAb) palivizumab is associated with protection against
hospitalisation secondary to RSV infection. Finally, an
inverse correlation between maternal antibody virus neutral-
isation (VN) titres and protection against hospitalisation was
reported.23,24
Four potential target populations for RSV vaccines exist,
namely young infants, older children, pregnant women and
the elderly (>65 years). The most advanced current strategies
for RSV vaccine development are live attenuated RSV vaccine
strains and recombinant viral vectors expressing RSV anti-
gens. All vaccines currently in clinical trials are detailed in
Table 2.
Live attenuated RSV vaccines have been studied for several
decades. Historically, these vaccines were produced by a
combination of chemical mutagenesis and serial passage at
progressively lower temperatures. Cold passaged, tempera-
ture-sensitive (cpts) vaccines were created with the rationale
of restricting viral replication to nasal passages rather than
the warmer lower airways, thereby preventing LRTI. Prom-
ising data regarding this vaccine strategy came from phase 1
Table 1. Results of WHO ICTRP search for relevant clinical trials
involving RSV therapeutics, prophylactics or vaccines
Total number of RSV clinical trials identified 160
Trials excluded due to date 54
Records excluded due to other reasons 61
Duplicate entries 11
Non-drug related studies 34
Not relevant to RSV 3
Palivizumab studies 9
Studies not involving new drugs 4
Relevant records included in the review 45
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testing of the cpts-248/404 vaccine in infants aged 1–
2 months.25 The study reported virus replication in most
recipients (19/22) following the first vaccine dose, but no
replication in the vast majority of infants (17/19) following a
second dose 1 month later. This demonstrated that vaccine-
induced immunity is possible in this age group. However,
unacceptable upper respiratory tract congestion precluded
further development of this vaccine. Reassuringly, this and
other recent studies of live attenuated vaccines found no
evidence of FI-RSV-like enhanced disease.26
Unfortunately, this approach to RSV vaccines has suffered
many setbacks, with major difficulties in balancing vaccine
Table 2. The most recently registered clinical trials for RSV vaccines, prophylactics and therapeutics since 2008
Drug name
Clinical
trial status
Manufacturer/
Institution Experimental approach Outcome
Vaccines
Live attenuated
MEDI-559 Phase 1/2a MedImmune LLC Live attenuated Increased rate of LRTIs in vaccine
recipients, further study ongoing
RSV LID DM2-2 Phase 1 NIAID Recombinant live attenuated RSV Estimated completion May 2016
RSV cps2, Lot
RSV#005A
Phase 1 MedImmune, NIAID Recombinant live Attenuated RSV Estimated completion May 2015
Chimeric/vectored
RSV 001 Phase 1 Okairos Adenovirus vector and an
MVA vector encoding RSV antigens
Commenced May 2013
Outcome awaited
MEDI-534 Phase I MedImmune LLC Chimeric/vectored Genetic variants within vaccine
detected. Ongoing research.
Nanoparticle
RSV F nanoparticle
vaccine
Phase 2 Novavax Recombinant RSV F protein particle Commenced October 2013
Outcome awaited
Subunit
MEDI 7510 Phase 1a MedImmune LLC RSV sF antigen + synthetic
glucopyranosyl lipid A adjuvant
Estimated completion July 2015
RSV F subunit
vaccine
Phase 1 Novartis vaccines F subunit vaccine Estimated completion September 2016
GSK3003891A Phase 1 GlaxoSmithKline
(GSK) Biologicals
Prefusion F subunit vaccine Estimated completion March 2015
Prophylactics
Motavizumab
(Numax/MEDI-524)
Phase 3
(completed 2008)
MedImmune Affinity-matured palivizumab Increased type I hypersensitivity.
No FDA approval
MEDI 557 Phase 1 MedImmune Recombinant human
monoclonal antibody
Completed May 2013. Data not available
MEDI 8897 Phase 1b/2a MedImmune Human RSV monoclonal antibody Estimated completion December 2014
RI-001 Phase 2 ADMA biologics Inc Polyclonal immune globulin.
Delivered intravenously
Completed May 2010
REGN2222 Phase 3 Regeneron
pharmaceuticals
Human monoclonal anti-RSV F
antibody
Estimated completion date February 2015
Therapeutics
GS-5806 Phase 2b Gilead RSV entry inhibitor Estimated completion June 2015
ALN-RSV01 Phase 2b
(completed
May 2012)
Ablynx siRNA targeting the N protein Reduced bronchiolitis obliterans
post-RSV infection in lung
transplant recipients.
ALS-008176 Phase 2a Alios biopharma Inc. Nucleoside analogue Estimated completion August 2014
Danirixin Phase 1 GlaxoSmithKline CXCR2 antagonist.
Inhibition of neutrophil
activation
Estimated completion July 2014
RV568 Phase 1 Respivert Ltd Kinase inhibitor Completed 2011. Data not available
MDT-637 Phase 1 MicroDose
Therapeutx, Inc
Fusion inhibitor Commenced 2013. Data not available
ALX-0171 Phase 1 Ablynx Nanobody Commenced 2014
Data not available
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attenuation and immunogenicity. Indeed, early attempts
with under-attenuated vaccines were associated with higher
rates of nasal congestion, fever, LRTI, cough and otitis
media.25,27,28 Conversely, over-attenuated vaccines in RSV-
na€ıve children were associated with greatly reduced infectiv-
ity and concomitant reduced nasal cytokine levels, suggesting
that they were unsuitable vaccine candidates.29,30
Reverse genetics technology for RSV, which enables
modulation of the viral genome, facilitated the introduction
of combinations of specific attenuating mutations to develop
new vaccine candidates, for example MEDI-559 or
RSVDNS2D1313/1314L. There are four live attenuated RSV
vaccines that have recently completed or are currently in
phase 1/2a clinical trials. Data from these trials are expected
in 2015 and/or 2016.
Following the initial promise of the cpts-248/404 RSV
vaccine in infants, the virus was further mutated in an effort
to improve its attenuation in view of adverse effects.
Preclinical studies identified the attenuating effect of deletion
of the SH gene and introduction of a temperature-sensitive
mutation in the L gene (N1321). The resultant live attenu-
ated RSV vaccine candidate was designated rA2cp248/404/
1030/DSH.30,31 The vaccine was well tolerated in RSV-na€ıve
infants, but induced limited virus neutralising (VN) antibody
responses in infants under 6 months and demonstrated
genetic instability in 30% of isolates recovered following
vaccination.31 MEDI-559, a derivative of rA2cp248/404/
1030/DSH, was subsequently engineered with further codon
changes at the 248 (L protein codon 831) and 1030 (L
protein codon 1321) attenuating mutation sites. A study in
RSV-seronegative infants aged 5–24 months demonstrated
significant induction of RSV VN antibodies in 59% of
MEDI-559 vaccine recipients. However, genetic instability in
its attenuating mutations was evident. More worryingly,
although numbers were low, there was an increased rate of
medically attended LRTIs, including wild-type RSV infec-
tions, in the vaccine versus placebo cohorts during follow-
up.32–34
In an effort to produce a more stable vaccine candidate,
RSV cps2 Lot RSV#005A was engineered from MEDI-559
with five nucleotide changes (248 mutation, position L831:
a10990g; compensatory mutation, position S1313: a12434t/
g12435c/c12436a; 1030 mutation: N1321K, t12460a) known
to confer genetic stability to the attenuating mutations.35
This vaccine is currently undergoing phase 1 clinical trials
with an estimated completion date of May 2015.
A second vaccine candidate was derived from MEDI-559
with a deletion of the codon at position 1313, instead of the
S1313 mutation described above for RSV cps2 Lot
RSV#005A. This candidate also included deletion of the
NS2 gene and an amino acid change at position 1314 in the L
protein (I1314L) and was designated RSVDNSD1313/1314L.
Preclinical studies showed that this candidate replicates at
37°C.33 It had comparable viral shedding in nasal washings to
MEDI-559 in chimpanzees, indicating similar levels of
attenuation.27 This vaccine also induced similar or higher
serum VN antibodies in juvenile chimpanzees compared to
both MEDI-559 and the RSV cps-2.33 A phase 1 clinical trial
of RSVDNS2D1313/1314L is underway, designed to deter-
mine its clinical safety and genetic stability profiles.
Additional non-essential gene deletion mutants were also
explored to produce live attenuated vaccines. MEDI DM2-2
vaccine has a deletion of the M2-2 gene. Recombinant viruses
with M2-2 gene deletion were shown in vitro to have
decreased RNA replication, attenuated virus growth kinetics
and concomitant increases in F and G protein expression.36
As F and G proteins are the principal RSV vaccine targets, the
combination of growth attenuation and increased F and G
protein expression render this vaccine candidate of consid-
erable interest. MEDI DM2-2 is currently undergoing a phase
1 clinical trial for safety and immunogenicity in adults,
seropositive children and seronegative infants.
MEDI-534 is a recombinant chimeric bovine/human
parainfluenza virus type 3 (b/hPIV3), with a genome
composed of the hPIV3 HN and F genes, the bPIV3 N, P,
M and L genes, and the RSV F gene. The RSV F gene was
inserted as an extra-transcription unit between the b/
hPIV3 N and P genes.37 As such, MEDI-534 constitutes a
potential bivalent vaccine against both hPIV3 and RSV.
Following translation, the precursor RSV F0 is proteolytically
cleaved by furin-like proteases to F1 and F2 subunits, which
subsequently form F1/F2 heterodimers linked by disulphide
bridges to produce mature F.38 Infection of Vero cells with
MEDI-534 or wild-type RSV A2 resulted in similar expres-
sion of RSV F1 protein, indicating efficient RSV F protein
expression. However, altered RSV F protein cleavage follow-
ing MEDI-534 infection was also evident, although this did
not appear to compromise its vaccine potential. Indeed,
MEDI-534 induced protective immunity in Syrian golden
hamsters against challenge with RSV A2.37 However, testing
of the vaccine in RSV-seronegative infants revealed genetic
variation of MEDI-534 recovered in nasal washes and a
higher rate of reported runny/stuffy nose in all vaccine
recipients versus placebo within 14 days of vaccination. The
genetic mutations included the introduction of premature
stop codons within the RSV F open reading frame, consistent
with loss of RSV F protein expression. Subsequent in vitro
testing involving multiple passages in MRC-5 cells also
demonstrated acquisition of mutations that resulted in
increased viral replication and a reduction in RSV F protein
expression.39,40 These data suggest that in vitro testing for
genetic stability should be considered prior to clinical
development of such RSV vaccines.
Another recent virus-vectored RSV vaccine strategy to
enter clinical trials is the prime/boost regime developed by
Okairos. It involves simian adenovirus (PanAd3-RSV) and
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modified vaccinia Ankara (MVA-RSV) virus vectors express-
ing RSV F, N and M2-1 proteins. Priming is with PanAd3-
RSV, either intranasally or intramuscularly (IM), while IM
boosting is with either PanAd3-RSV or MVA-RSV. While no
peer-reviewed data were found, preclinical data described in
patent WO2014005643A1 demonstrated induction of strong
protective immunity in mice and cotton rat models of RSV
infection. A phase 1 clinical trial in healthy adult volunteers
is currently underway and will investigate the safety and
immunogenicity of IN or IM PanAd3-RSV priming and IM
boosting with either PanAd3-RSV or MVA-RSV.
A number of subunit vaccine candidates are currently
under clinical investigation. These vaccines are based on the
RSV F protein. The Novavax RSV F nanoparticle vaccine was
engineered using the baclofen/sf9 insect cell system to
produce post-fusion F protein.41 Cotton rats immunised
with the nanoparticles demonstrated strong protective effi-
cacy against RSV challenge. In phase 1 clinical trials in adults,
the vaccine was well tolerated and induced 4- to 20-fold
increases in anti-RSV F IgG in vaccine versus placebo
recipients.41–43 Clinical trials to investigate safety and
immunogenicity following IM administration have recently
begun in seropositive infants (24–72 months) (phase 1),
adults >60 years (phase 2) and women of child-bearing age
(phase 2).
MEDI-7510 is a subunit vaccine containing post-fusion
RSV F formulated with the synthetic TLR-4 agonist gluco-
pyranosyl lipid A adjuvant. Glucopyranosyl lipid A is known
to enhance the magnitude of antibody responses to influenza
vaccines.44 A phase 1b study is currently recruiting healthy
adults >60 years to study safety and immunogenicity
following IM administration.
Novartis are developing a subunit vaccine composed of
post-fusion RSV F trimers adsorbed to aluminium hydrox-
ide. It induced evidence of serum VN activity and strong
protective efficacy in a cotton rat model.45 A phase 1 clinical
trial of Novartis vaccine in healthy adults, to assess safety and
immunogenicity following IM administration, is due for
completion in 2016.
Recent structural data indicated that RSV F adopts two
conformations, the pre- and post-fusion configurations.46
RSV subunit vaccines described above are based on the post-
fusion conformation. However, most RSV neutralising
antibodies in human sera following RSV infection are
directed towards the pre-fusion configuration, suggesting
that vaccines based on post-fusion RSV F may be subopti-
mal.47 Accordingly, a number of pre-fusion F candidates are
in preclinical development, including the NIH pre-fusion
RSV F vaccine, which induced enhanced serum VN titres in
mice and non-human primates relative to post-fusion F
antigen.46 To our knowledge, the only pre-fusion F antigen
vaccine currently in clinical trials is GSK3003891A. Patent
no. WO2010149745 reported induction of VN antibodies
and protection against RSV challenge in a mouse model of
RSV infection following IM immunisation with prefusion F
in various formulations.48 Phase 1 studies of these vaccine
formulations are currently underway in healthy adults to
assess safety, reactogenicity and immunogenicity.
Despite the increasing variety of RSV vaccine strategies
currently under investigation, it is clear from the number of
RSV vaccine candidates failing to progress beyond phase 1/2a
trials that a number of challenges remain. Historically, there
has been a considerable disconnect between excellent efficacy
in animal models and limited or no clinical effectiveness for
RSV vaccines. This might be explained in part by the capacity
of RSV proteins (e.g. F, G, NS1, NS2), to modulate immune
responses following infection of humans.49,50 Therefore, the
possibility remains that these RSV vaccine strategies may
result in compromised or poorly protective immune
responses in humans, as is evident following natural RSV
infection. In our opinion, detailed understanding of human
immune responses to RSV infection and/or vaccination
would greatly help RSV vaccine development.
Prophylactics
RespiGam (RSV immune globulin IV) was the first RSV-
specific drug ever approved. It consisted of human polyclonal
serum screened for high RSV VN activity and was transfused
over several hours in relatively large volumes to infant
recipients at high risk of developing severe RSV-LRTI
(prematurity, bronchopulmonary dysplasia or chronic lung
disease).51 In parallel with RespiGam, a humanised MAb
(palivizumab) was developed and FDA-approved, and has
since superseded the use of RespiGam due to increased RSV
specificity and a simpler administration protocol. Pali-
vizumab recognises antigenic site 2 on RSV F and is injected
IM each month (15 mg/kg) throughout the annual RSV
season. It reduced RSV-related hospitalisation rates by 45–
55% in a cohort of infants that were classed as high risk for
developing severe RSV-LRTI.52 Although palivizumab
appears to provide some protection against severe RSV-
related disease, the cost-benefit ratio is such as to restrict the
use to high-risk infants.53 Motavizumab, an affinity-matured
derivative of palivizumab with a 20-fold increase in VN
activity, was found to be more efficient than palivizumab at
preventing severe RSV-related disease in high-risk infants.54
Unfortunately, it also caused hypersensitivity reactions in
some infant recipients and consequently failed to obtain FDA
approval.55
A major problem associated with palivizumab is the
requirement for repeated monthly injections. To help
overcome this, MedImmune developed third-generation
RSV-specific YTE mutant (amino acid substitutions
M252Y/S254T/T256E) MAbs, including MEDI-557 and
MEDI-8897, derived from motavizumab and D25, respec-
tively. D25 is a previously described anti-RSV F MAb isolated
RSV vaccines, prophylactics, and antivirals
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directly from human B cells.56 The YTE mutations confer
extended half-lives.57 The goal was to develop a pharmaceu-
tical requiring a single annual injection. However, there are
currently no published data on either MAb, although clinical
trials in healthy adults or preterm infants were recently
undertaken (Table 2).
REGN2222 a fully human MAb directed against RSV F was
derived from RSV-F-immunised transgenic mice expressing
human immunoglobulin germ line sequences. This is the
only RSV-specific drug to reach phase 3 clinical trials since
motavizumab, for which preterm infants are currently being
recruited. Although we were unable to locate peer-reviewed
data, patent US20140271653 reported a 15- to 17-fold greater
in vitro VN activity against RSV A2 and superior prophylaxis
in a cotton rat model of RSV infection compared with
palivizumab.58
Therapeutics
Recent efforts to develop RSV antiviral drugs have focused
primarily on fusion inhibitors or virus gene silencing.
Ribavirin, a nucleoside analogue inhibitor of viral RNA
synthesis, is licensed for use in haematopoietic transplant
recipients with RSV-LRTI. Recent data suggested it may play
a role in reducing mortality in this patient cohort.59
However, its efficacy and safety profile remains controversial
due to inconclusive evidence from small, under-powered
studies.60,61
A novel RSV fusion inhibitor, GS-5806, efficiently neu-
tralised a large panel of RSV clinical strains in vitro.62 Studies
in cotton rats suggested a trend towards a dose-dependent
reduction in lung viral titres following intraperitoneal
administration 1 hour after RSV challenge. In an exciting
development, a RSV strain Memphis 37 challenge trial in
healthy adults with low serum RSV VN activity showed
reduced mucus production, clinical severity scores, and mean
peak viral loads in nasal washes following treatment.63 It is
noteworthy, however, that GS-5806 was administered orally
following RSV detection but before symptoms developed.63
The excitement generated by these data, therefore, must be
tempered by the fact that the experimental protocol poorly
reflects clinical reality, in which symptomatic infections will
be evident before drug administration. However, this con-
cern may be resolved in a forthcoming trial in infants
hospitalised with RSV (due for completion by June 2015).
RNA interference (RNAi) is a process that targets specific
mRNAs for degradation, thereby abrogating expression of
the encoded proteins. Synthetic RNAi derivatives, such as
short interfering RNAs (siRNA), were shown to be effective
therapeutics against several genetic diseases, cancers and viral
infections.64–67 ALN-RSV01 is an siRNA directed against the
RSV nucleocapsid (N) protein.68 A clinical trial in otherwise
healthy RSV-infected adults showed a trend towards reduced
mean viral titres and clinical severity scores, although neither
reached statistical significance.69 ALN-RSV01 has also been
tested in a small cohort of RSV-infected lung transplant
recipients (n = 24; ALN-RSV01 = 16, placebo = 8). The
incidence of bronchiolitis obliterans syndrome was greatly
reduced, with only 63% of patients receiving ALN-RSV01
developing new or progressive bronchiolitis obliterans,
compared with 50% of the placebo group.70 No data have
been published on ALN-RSV01 since 2011, but development
appears to be ongoing.
In a similar RSV Memphis 37 human challenge model as
described above, the nucleoside analogue, ALS-008176, was
shown to significantly reduce viral load and accelerate viral
clearance, with a trend towards reduced clinical severity.71
However, the data remain to be peer-reviewed. As was
reported for GS-5806, this drug was administered shortly
after a positive PCR test for RSV in nasal washes. As such, the
time at which the drug was administered may reduce the
clinical significance of these data. A phase 2a safety study
with ALS-008176 in infants hospitalised with RSV is ongoing,
and preliminary efficacy data are also expected from this
study.
MDT-637 is a fusion inhibitor delivered as an inhaled dry
powder. Preclinical data demonstrated that the drug can be
dispersed through the upper and lower airways using this
delivery system.72 A proof-of-concept efficacy trial using the
RSV Memphis 37 human challenge model was initiated in
2013. No data have yet been published, but proprietary
information suggested this drug is more potent than
ribavirin.
Single-domain camelid-derived antibodies, or nanobodies,
are antibody fragments that retain the antigen-binding ability
of the heavy chain antibody.73 ALX-0171 is a trivalent RSV-
F-specific nanobody with potent VN activity.74 Its therapeu-
tic potential in a neonatal lamb model of RSV infection was
recently reported at an international RSV conference.75
Treatment initiation by inhalation post-RSV challenge, even
following appearance of symptoms, resulted in a dramatic
decline in cultivatable virus and reduced lung viral antigen
expression, lung viral lesions and histological changes.75,76
ALX-0171 treatment also exerted a positive effect on clinical
parameters (e.g. respiratory rate, wheeze, temperature) and
was well tolerated. It was reported to be safe in phase 1 safety
and pharmacokinetic studies in adults and a phase 1/2a study
in RSV-infected hospitalised infants aged 5–24 months is
ongoing77 (Table 2).
Inflammatory responses to RSV infection are thought to
be major components of RSV pathogenesis. In particular,
neutrophil infiltration to the lungs is associated with severe
disease.78 Targeting inflammatory responses is, therefore,
being pursued as a strategy for treating RSV-associated
disease. Danirixin (GSK1325756) is a reversible CXCR2
antagonist originally developed as an anti-inflammatory
agent for disorders associated with neutrophil accumulation,
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such as chronic obstructive pulmonary disease.79 As neutro-
phil infiltration is an important component of RSV patho-
genesis, a clinical trial was initiated to determine the capacity
of danirixin to inhibit neutrophil activation in RSV-infected
infants. Specifically, the relative capacity of escalating doses
of danirixin to block expression of the activation marker
CD11b on CXCL1-stimulated peripheral blood neutrophils
derived from RSV-infected children <2 years of age or
healthy adults was examined. Although study completion
was expected in July 2014, data remain to be published.
Neutrophil responses were also targeted by the narrow
spectrum kinase inhibitor, RV568, which was initially
developed for the treatment of inflammatory diseases, such
as rheumatoid arthritis. It was recently repositioned for
investigation against RSV infection.80 In a RSV Memphis 37
human challenge trial, subjects treated intranasally bis in die
with RV568 from 24 hours post-challenge showed a reduc-
tion in IL-8 levels in nasal washes relative to untreated
controls.81 Although evidence suggests that increased IL-8
levels are associated with more severe RSV disease and IL-8 is
a neutrophil chemotactic, this study showed no effect on
clinical severity.82
Many of the therapeutic studies described above used viral
load as the primary outcome. However, there is conflicting
evidence as to whether viral load correlates with severe
disease in humans. Some studies demonstrated a correlation
between increased viral load and disease severity,83,84 but
another found no correlation.85 A combination of host and
viral factors are likely to contribute to the overall pathogen-
esis of RSV.86 As such, a combination of antiviral and anti-
inflammatory agents may be necessary for a successful
therapeutic. In this regard, identification and a comprehen-
sive understanding of host factors implicated in RSV
pathogenesis will greatly facilitate the design and outcomes
of clinical trials involving RSV drugs.
Conclusions
Respiratory syncytial virus is the most important cause of
LRTI in young children worldwide and continues to be a
major unmet medical need for most infants. Despite the
generation of extensive information regarding RSV patho-
genesis in animal and cell infection models, the mechanisms
of RSV pathogenesis in humans remain elusive. With the
exception of palivizumab and RespiGam, no other successful
prophylactics are licensed for use. Furthermore, no RSV-
specific therapeutic or vaccine has been licensed. Encourag-
ingly, there has been an increase recently in RSV vaccines and
pharmaceuticals entering clinical trials. These products were
often derived from a greater understanding of RSV attenu-
ation and structural biology, and the application of novel
technologies, such as nanobodies, nanoparticles, siRNA and
small molecule inhibitors. However, as RSV pathogenesis is
thought to be immune mediated and primary infection does
not prevent re-infection, a deeper fundamental understand-
ing of RSV disease mechanisms and immune modulation in
humans is likely to be necessary for successful clinical
development of vaccines, prophylactics or therapeutics.
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Appendix 1: National clinical trials registries
included in the WHO registry of clinical
trials
 Australian New Zealand Clinical Trials Registry, last
data file imported on 8 December 2014.
 Chinese Clinical Trial Registry, last data file imported on
8 December 2014.
 ClinicalTrials.gov, last data file imported on 8 December
2014.
 EU Clinical Trials Register, last data file imported on 8
December 2014.
 ISRCTN, last data file imported on 8 December 2014.
 The Netherlands National Trial Register, last data file
imported on 9 December 2014.
 Brazilian Clinical Trials Registry (ReBec), last data file
imported on 9 December 2014.
 Clinical Trials Registry – India, last data file imported on
9 December 2014.
 Clinical Research Information Service – Republic of
Korea, last data file imported on 9 December 2014.
 Cuban Public Registry of Clinical Trials, last data file
imported on 9 December 2014.
 German Clinical Trials Register, last data file imported
on 9 December 2014.
 Iranian Registry of Clinical Trials, last data file imported
on 10 November 2014.
 Japan Primary Registries Network, last data file
imported on 9 December 2014.
 Pan African Clinical Trial Registry, last data file
imported on 9 December 2014.
 Sri Lanka Clinical Trials Registry, last data file imported
on 9 December 2014.
 Thai Clinical Trials Register (TCTR), last data file
imported on 9 December 2014.
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